Table 3.
Opioid-related visits | Nonopioid-related visits | CCS label | ||
---|---|---|---|---|
Rank | Estimated percent | Rank | Estimated percent | |
1 | 16.8 | 1 | 30.8 | Essential hypertension (CCS 98) |
2 | 16.1 | 13 | 3.0 | Other nervous system disorders (CCS 95) |
3 | 16.0 | 7 | 9.7 | Chronic obstructive pulmonary disease and bronchiectasis (CCS 127) |
4 | 11.2 | 2 | 13.1 | Congestive heart failure; nonhypertensive (CCS 108) |
5 | 10.8 | — | <0.1 | Mood disorders (CCS 657) |
6 | 7.8 | 3 | 12.9 | Cardiac dysrhythmias (CCS 106) |
7 | 7.1 | 4 | 12.6 | Coronary atherosclerosis and other heart disease (CCS 101) |
8 | 6.6 | 5 | 12.0 | Diabetes mellitus without complication (CCS 49) |
9 | 4.6 | — | <0.1 | Alcohol-related disorders (CCS 660) |
10 | 4.5 | 9 | 5.5 | Hypertension with complications and secondary hypertension (CCS 99) |
11 | 4.2 | — | <0.1 | Screening and history of mental health and substance abuse codes (CCS 663) |
12 | 4.1 | 6 | 10.1 | Disorders of lipid metabolism (CCS 53) |
13 | 4.0 | — | 0.5 | Respiratory failure; insufficiency; arrest (adult) (CCS 131) |
14 | 2.6 | — | 1.6 | Anxiety disorders (CCS 651) |
15 | 2.2 | — | 1.6 | Nutritional deficiencies (CCS 52) |
— | <0.1 | 8 | 6.8 | Delirium, dementia, and amnestic and other cognitive disorders (CCS 653) |
— | 1.2 | 10 | 5.3 | Chronic kidney disease (CCS 158) |
— | 1.2 | 11 | 3.8 | Esophageal disorders (CCS 138) |
— | <0.1 | 12 | 3.7 | Thyroid disorders (CCS 48) |
— | <0.1 | 14 | 2.0 | Conduction disorders (CCS 105) |
— | 0.8 | 15 | 1.7 | Acute cerebrovascular disease (CCS 109) |
Note. CCS = Clinical Classification Software (available from https://www.hcup-us.ahrq.gov/toolssoftware/ccs/AppendixASingleDX.txt). Estimates were aggregated from across the first five chronic conditions listed on the record. The opioid misuse subpopulation does not include diagnostic codes indicating chronic opioid misuse, as this overlapped with subpopulation definition. Frequencies were aggregated across all study years.